Vaxcyte, Inc. (PCVX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は San Carlos, CA, アメリカ. 現CEOは Grant E. Pickering.
PCVX を有する IPO日 2020-06-12, 414 名の正社員, に上場 NASDAQ Global Select, 時価総額 $9.03B.
Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing novel protein vaccines to prevent and treat bacterial infectious diseases. The company's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials for invasive pneumococcal disease and pneumonia. Vaxcyte's pipeline also includes VAX-XP to address emerging strains and antibiotic resistance, VAX-A1 targeting Group A Strep, and VAX-PG designed to treat periodontitis. Founded in 2013 and headquartered in San Carlos, California, the company was formerly known as SutroVax, Inc. before rebranding in May 2020.
